[ TP Therapeutics raises $45M in Series C funding ]
TP Therapeutics has raised $45 million in Series C funding.
Founded in 2013, TP Therapeutics is a structure-based drug design pharmaceutical company founded by Dr. J. Jean Cui, the lead inventor of Pfizer’s Xalkori(TM), the precision oncology drug for non-small cell lung cancer (NSCLC).
The company will use the fresh funding to continue development of its lead program, TPX-0005, for treatment of naïve and resistant patients with ALK, ROS1 or NTRK abnormal genes and for the advancement of several pre-clinical pipeline projects.
|City||San Diego, California|
|Founder / CEO||Dr. Y. Peter Li|
|Investors||SV Tech Ventures|
|Lilly Asia Ventures|
|Cormorant Asset Management|